China SXT Pharmaceuticals, Inc.
No SEC Form 4 filings for $SXTC in the last 30 days.
See all $SXTC insider activity →China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) shares rose about 27% during Aug 10-14, 2026, with the article citing heightened optimism and a technical momentum breakout from a $3.22-$3.50 range to a $4.73 high and $4.20 close. It also notes revenue near $1.14M and cash about $28.18M versus liabilities about $5.05M.
China SXT Pharmaceuticals (NASDAQ:SXTC) shares fell 77% after it announced a $9 million registered direct offering. The company will sell 4.5 million units at $2.00 each, with each unit including one Class A share and a warrant exercisable at $3.20, expiring in one year. Closing is expected around July 24, 2025.
China SXT Pharmaceuticals said in an SEC filing it may sell up to $100 million of Class A ordinary shares under an at-the-market program, issuing shares from time to time on Nasdaq or other venues. Univest Securities will act as sales agent and receive a 3% commission plus certain expenses. The stock closed at $1.68 (+0.60%) and rose 25.6% after hours to $2.11.
Over the past 7 days, alphai's AI scored 1 news story mentioning SXTC (China SXT Pharmaceuticals, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent SXTC coverage spans market movers, financial news and corporate actions.
Move appears momentum-driven with thin fundamentals, so traders may treat it as a short-term volatility trade rather than a fundamental repricing.
The registered direct offering at $2.00 per unit with immediately exercisable warrants is a near-term dilution overhang.
ATM equity sales raise near-term dilution/overhang risk, but the after-hours pop suggests traders are initially focusing on funding optionality.
The share re-classification introduces a dual-class share structure, potentially affecting voting power and shareholder control. This change may influence investor sentiment and stock performance.
China SXT Pharmaceuticals (SXTC) reported unaudited financial results for H1 2025, highlighting reliance on a China-based VIE structure and associated regulatory, capital control, and tax risks. The company’s somewhat-bearish sentiment suggests cautious investor outlook.
alphai scores every news story that mentions SXTC with an AI model for sentiment and relevance, and aggregates insider trades from China SXT Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) shares rose about 27% during Aug 10-14, 2026, with the article citing heightened optimism and a technical momentum breakout from a $3.22-$3.50 range to a $4.73 high and $4.20 close. It also notes revenue near $1.14M and cash about $28.18M versus liabilities about $5.05M.
5 min readChina SXT Pharmaceuticals (NASDAQ:SXTC) shares fell 77% after it announced a $9 million registered direct offering. The company will sell 4.5 million units at $2.00 each, with each unit including one Class A share and a warrant exercisable at $3.20, expiring in one year. Closing is expected around July 24, 2025.
3 min readChina SXT Pharmaceuticals said in an SEC filing it may sell up to $100 million of Class A ordinary shares under an at-the-market program, issuing shares from time to time on Nasdaq or other venues. Univest Securities will act as sales agent and receive a 3% commission plus certain expenses. The stock closed at $1.68 (+0.60%) and rose 25.6% after hours to $2.11.
4 min readChina SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) announced a share re-classification, effective March 24, 2026, which will introduce a dual-class share structure. The re-classification was approved by shareholders on July 28, 2025, establishing Class A Ordinary Shares with no par value and Class B Ordinary Shares entitling holders to fifty votes per share. Existing shares held through nominees will be automatically adjusted to reflect this change.
2 min readChina SXT Pharmaceuticals (SXTC) filed a Form 6-K on December 31, 2025, disclosing unaudited financial results for the first half of 2025, covering the period ended September 30, 2025. The company highlighted its continued reliance on a China-based VIE structure and noted significant regulatory, capital control, and tax risks that could impact its control over the VIE and its ability to remit dividends to investors. These factors pose key risks for investors and stakeholders.
3 min read
